These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34970515)

  • 1. Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients.
    Frontino G; Raouf T; Canarutto D; Tirelli E; Di Tonno R; Rigamonti A; Cascavilla ML; Baldoli C; Scotti R; Leocani L; Huang SC; Meschi F; Barera G; Broccoli V; Rossi G; Torchio S; Chimienti R; Bonfanti R; Piemonti L
    Front Pediatr; 2021; 9():755365. PubMed ID: 34970515
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.
    Kondo M; Tanabe K; Amo-Shiinoki K; Hatanaka M; Morii T; Takahashi H; Seino S; Yamada Y; Tanizawa Y
    Diabetologia; 2018 Oct; 61(10):2189-2201. PubMed ID: 30054673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.
    Jagomäe T; Seppa K; Reimets R; Pastak M; Plaas M; Hickey MA; Kukker KG; Moons L; De Groef L; Vasar E; Kaasik A; Terasmaa A; Plaas M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
    Toots M; Seppa K; Jagomäe T; Koppel T; Pallase M; Heinla I; Terasmaa A; Plaas M; Vasar E
    Sci Rep; 2018 Jul; 8(1):10183. PubMed ID: 29976929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome.
    Seppa K; Toots M; Reimets R; Jagomäe T; Koppel T; Pallase M; Hasselholt S; Krogsbæk Mikkelsen M; Randel Nyengaard J; Vasar E; Terasmaa A; Plaas M
    Sci Rep; 2019 Oct; 9(1):15742. PubMed ID: 31673100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model.
    Seppa K; Jagomäe T; Kukker KG; Reimets R; Pastak M; Vasar E; Terasmaa A; Plaas M
    Sci Rep; 2021 Jan; 11(1):2275. PubMed ID: 33500541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.
    Abreu D; Stone SI; Pearson TS; Bucelli RC; Simpson AN; Hurst S; Brown CM; Kries K; Onwumere C; Gu H; Hoekel J; Tychsen L; Van Stavern GP; White NH; Marshall BA; Hershey T; Urano F
    JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34185708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wolfram syndrome: new pathophysiological insights and therapeutic strategies.
    Mishra R; Chen BS; Richa P; Yu-Wai-Man P
    Ther Adv Rare Dis; 2021; 2():26330040211039518. PubMed ID: 37181110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options.
    Png D; Yeoh E; Tan C; Lim SC
    J Investig Med High Impact Case Rep; 2023; 11():23247096221150631. PubMed ID: 36644884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
    von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
    Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.
    Schiavon M; Visentin R; Göbel B; Riz M; Cobelli C; Klabunde T; Dalla Man C
    Diabetes Obes Metab; 2021 Aug; 23(8):1795-1805. PubMed ID: 33822469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Cases of Wolfram Syndrome Who Were Initially Diagnosed With Type 1 Diabetes.
    Silvestri F; Tromba V; Costantino F; Palaniappan N; Urano F
    AACE Clin Case Rep; 2022; 8(3):128-130. PubMed ID: 35602877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.